Resistance mutation info of drug
Drug General Information | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug ID | D0ZU9R | ||||||||||
Drug Name | Ritonavir | ||||||||||
Synonyms | Norvir; RIT; RTV; Norvir Sec; Ritonavir [USAN]; ABT 538; ABT 84538; ABT538; Abbott 84538; A-84538; ABBOTT-84538; ABT-538; DRG-0244; Norvir (TM); Norvir (TN); Ritonavir (JAN/USAN/INN); N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide; 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate; 538, ABT | ||||||||||
Drug Type | Small molecular drug | ||||||||||
Therapeutic Class | Anti-HIV Agents | ||||||||||
Company | Abbott Laboratories | ||||||||||
Structure | |||||||||||
Drug Resistance Mutations | |||||||||||
Target Name | HIV Protease | Target Info | |||||||||
Uniprot ID | POL_HV1B1(501-599) | ||||||||||
Species | Human immunodeficiency virus type 1 (HIV-1) | ||||||||||
Reference Sequence |
PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYD QILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF [Human immunodeficie ncy virus type 1 (HIV-1)] |
||||||||||
Targeted Disease | HIV infection | ||||||||||
Drug Resistance Mutations |
|
||||||||||
References | |||||||||||
REF 1 | Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother. 2009 Nov;64(5):938-44. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.